A Thorough QT Study of TR-701free Acid (FA) in Healthy Subjects

To assess the effects of a single therapeutic (200 mg) and supratherapeutic of oral TR-701
free acid (FA) versus placebo on QT interval corrected for heart rate using Fridericia's
formula (QTcF) in healthy subjects.

Inclusion Criteria:

- Male or female subjects between 18 and 45 years of age, inclusive.

- Healthy males and females with no clinically significant abnormalities.

- Body mass index ≥18.0 kg/m2 and ≤30.0 kg/m2

Exclusion Criteria:

- Sustained supine systolic blood pressure >140 or <100 mmHg or a diastolic blood
pressure >90 or <60 mmHg at the Screening and Day 1 Visit.

- Abnormal ECG at Screening or Day -1 Visits indicating a second or third-degree
atrioventricular block, or QRS >110 msec, QTcF >450 msec for males and >470 msec for
females, PR interval >200 msec, or any rhythm other than sinus rhythm which is
interpreted by the Investigator as clinically significant - History of unexplained
infections or current signs of infection

- History of risk factors for Torsades de Pointes, including unexplained syncope, known
Long QT Syndrome, heart failure, myocardial infarction, angina, or clinically
significant abnormal laboratory assessments including hypokalemia, hypercalcemia,
hypomagnesemia, or family history of Long QT Syndrome or Brugada Syndrome